Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $2.7 million.

  • Nurix Therapeutics' Capital Expenditures rose 15.51% to $2.7 million in Q3 2025 from the same period last year, while for Aug 2025 it was $11.0 million, marking a year-over-year increase of 12.54%. This contributed to the annual value of $9.3 million for FY2024, which is 10.38% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Capital Expenditures of $2.7 million as of Q3 2025, which was up 1.35% from $2.7 million recorded in Q2 2025.
  • Nurix Therapeutics' 5-year Capital Expenditures high stood at $3.5 million for Q1 2025, and its period low was $843,000 during Q1 2021.
  • Over the past 3 years, Nurix Therapeutics' median Capital Expenditures value was $2.5 million (recorded in 2023), while the average stood at $2.4 million.
  • Per our database at Business Quant, Nurix Therapeutics' Capital Expenditures surged by 311.86% in 2022 and then plummeted by 61.28% in 2023.
  • Nurix Therapeutics' Capital Expenditures (Quarterly) stood at $862,000 in 2021, then surged by 197.56% to $2.6 million in 2022, then climbed by 0.78% to $2.6 million in 2023, then decreased by 18.57% to $2.1 million in 2024, then climbed by 15.51% to $2.7 million in 2025.
  • Its Capital Expenditures was $2.7 million in Q3 2025, compared to $2.7 million in Q2 2025 and $3.5 million in Q1 2025.